×

Biotech and Pharmaceuticals Life Sciences

  • LONDON, Nov 24- British privately owned biotech company Kymab has secured $100 million of funding from investors, including $36.5 million from China's Shenzhen Hepalink Pharmaceutical, to help to fund its pipeline of experimental antibody drugs. Kymab said on Thursday that ORI Healthcare Fund is also a new investor in the Cambridge- based business, which is...

  • *Head and neck cancer studies resume patient recruitment. LONDON, Nov 22- U.S. officials have given a green light for two clinical trials testing AstraZeneca's immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding. Shares in AstraZeneca gained around 1 percent on Tuesday as the...

  • LONDON, Nov 22- U.S. officials have given a green light for two clinical trials testing AstraZeneca's cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding. The British drugmaker said on Tuesday that one of the late-stage Phase III trials had already re-opened for new...

  • BRIEF-GSK FILES REGULATORY SUBMISSION OF CANDIDATE VACCINE@. *GSK files regulatory submission of candidate vaccine for prevention of shingles in Canada. *Says regulatory submission for candidate shingles vaccine is based on a comprehensive phase III clinical trial program.

  • The companies are racing rivals including Eli Lilly, Alder Biopharmaceuticals, Allergan and Teva Pharmaceuticals to have a new, more effective migraine treatment approved by U.S. and European regulators. Jefferies analyst Jeffrey Holford, in a note on Thursday, forecast $1.5 billion in peak sales for the drug, with estimates for Novartis reaping about $440...

  • *Says will meet with FDA "as soon as possible". Dynavax Chief Executive Eddie Gray said on Monday the company would meet with the FDA "as soon as possible" to discuss concerns raised by the agency in a "complete response letter." The company said the FDA, in its letter, sought information about certain "adverse events" during clinical trials, among other clarifications.

  • *Says to meet with FDA "as soon as possible". The drug developer said on Monday it received a "complete response letter" from the FDA, seeking information about certain "adverse events" during clinical trials, among other clarifications. Dynavax Chief Executive Eddie Gray said the company would meet with the FDA "as soon as possible" to discuss the letter.

  • The drug developer said it received a "complete response letter" from the FDA, seeking information about certain "adverse events" during clinical trials, among other clarifications. Dynavax said there was no request from the FDA for additional clinical trials and there were no apparent concerns about rare serious events. Dynavax Chief Executive Eddie Gray...

  • Nov 14- Dynavax Technologies Corp said on Monday the U.S. Food and Drug Administration had rejected the marketing application for its hepatitis B vaccine Heplisav-B, sending the company's shares tumbling 44 percent in premarket trading. The drug developer said it received a "complete response letter" from the FDA, seeking information about certain "adverse...

  • SAN FRANCISCO, Nov 9- U.S. companies reacted on Wednesday with caution to businessman Donald Trump's victory in the U.S. presidential election and pointed to uncertainty over his lack of clear policy proposals. Following campaign promises by Trump to renegotiate global trade agreements and make U.S. companies move factories back to the United States, over...

  • SAN FRANCISCO, Nov 9- U.S. companies reacted on Wednesday with caution to businessman Donald Trump's victory in the U.S. presidential election and pointed to uncertainty over his lack of clear policy proposals. Following campaign promises by Trump to renegotiate global trade agreements and make U.S. companies move factories back to the United States, over...

  • NATIONAL INSTITUTES OF HEALTH SAYS TESTING OF INVESTIGATIONAL INACTIVATED ZIKA VACCINE IN HUMANS BEGINS; 1 ST OF 5 PLANNED CLINICAL TRIALS TO TEST ZPIV VACCINE.

  • BOSTON, Nov 1- Billionaire hedge fund manager Daniel Loeb on Tuesday told clients that "idiosyncratic opportunities" have helped boost returns this year as a string of constant surprises has shaped markets, adding that more may be in store. With next week's U.S. presidential election looming large, Loeb's Third Point hedge fund wrote to clients in a letter seen by...

  • Nov 1- Pfizer Inc scrapped its high-profile cholesterol fighter after its effectiveness waned over time in large clinical trials, sending its shares 2 percent lower and prompting the company to trim its 2016 earnings forecast. Chief Executive Ian Read said in an interview that the effectiveness of Pfizer's drug waned in a significant number of patients...

  • Honoree Bob Dylan speaks onstage at the 25th anniversary MusiCares 2015 Person Of The Year Gala honoring Bob Dylan at the Los Angeles Convention Center on February 6, 2015 in Los Angeles, California.

    American winners of the prize will find that they're making less than any winner since 1988.

  • Google invests $4 billion a year on

    James Gautrey, global sector specialist for technology and telecoms at Schroders, approves of Google's ability to invest in riskier ventures.

  • Scientists create life without an egg

    Biologists were able to breed baby mice by injecting sperm into a non-viable type of embryo.

  • Executive Edge: Science behind earworms

    David Poeppel, New York University professor, explains why some songs are likely to stick in you mind than others.

  • Health care and life sciences lead Merck's lifted full-year guidance

    Marcus Kuhnert, the chief financial officer of Merck, comments on the company's earnings report and explains which areas of the business are doing well.

  • HIV virus in an image taken with transmission electron microscopy.

    A judge ruled that an HIV pill to prevent infection could be funded by the U.K.'s state health service, in a victory for AIDS campaigners.